Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 10/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | BRAF | P15056 | 3/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.79 |
| ▸ | RAF1 | P04049 | 2/20 | 0.79 |
| ▸ | KDR | P35968 | 2/20 | 0.79 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.79 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.79 |
| ▸ | NEK2 | P51955 | 2/20 | 0.79 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.79 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.79 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.79 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.79 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.79 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.79 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | KRAS | P01116 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20401191 | 0.91 | CYP2C19 (0.84) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL293377 | 0.91 | CYP2C19 (1.00) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL297589 | 0.90 | CYP2C19 (0.82) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL29898572 | 0.90 | CYP2C9 (1.00) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL294126 | 0.90 | CYP2C9 (1.00) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL2014333 | 0.89 | CYP2C19 (0.84) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL298927 | 0.89 | BRAF (0.89) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL20400626 | 0.89 | CYP2C9 (0.86) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL299099 | 0.89 | BRAF (0.86) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL2163098 | 0.89 | CYP2C19 (0.83) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427462-A1 | PYRROLO [2, 3. B]PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C19 2730/4885CYP2C9 2176/4885CYP3A4 3611/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | CYP2C19 2678/4885CYP2C9 2237/4885CYP3A4 2892/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | CYP2C19 2678/4885CYP2C9 2237/4885CYP3A4 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.